类风湿关节炎中b/tsDMARDs的关节特异性应答:瑞士SCQM注册研究
该纵向观察研究基于瑞士SCQM注册库,纳入治疗开始时至少有一个肿胀关节的RA患者,评估b/tsDMARDs治疗2年内各关节肿胀消退速度。主要分析聚焦初治TNFi患者,结果显示与腕关节相比,除第2、3掌指关节及部分分析中的膝关节外,其余关节肿胀消退更快;此模式在所有b/tsDMARDs中一致。
要点
- 腕关节、MCP2和MCP3关节肿胀消退速度慢于其他关节。
- 该关节特异性应答模式在所有b/tsDMARDs中一致。
- 对于这些关节受累者,可能需要更长评估期或关节腔内激素桥接治疗。
核心结论
- 腕关节、MCP2和MCP3关节在b/tsDMARDs治疗后肿胀消退较其他关节慢。
- 当这些关节受累时,可能需要更长治疗反应评估期和/或关节腔内激素桥接注射。
研究设计与样本
- 来自瑞士风湿病临床质量管理(SCQM)注册库的纵向观察研究。
- 纳入治疗开始时至少有一个肿胀关节并启动b/tsDMARDs的RA患者。
- 主要分析聚焦初治(bio-naïve)启动TNFi的患者,次要分析纳入所有b/tsDMARDs类别。
- 使用混合效应模型处理区间删失数据,评估2年随访期间肿胀关节消退时间。
- 比较28关节计数中单个关节与腕关节的改善速度。
主要发现
- 598例至少有一个肿胀关节的患者启动了TNFi。
- 1942例至少有一个肿胀关节的患者启动了b/tsDMARDs(阿巴西普242例、IL-6Ri 317例、JAKi 333例、利妥昔单抗176例、TNFi 874例)。
- 与腕关节相比,所有关节均显示更高的消退率,但MCP2/3关节及部分分析中的膝关节除外。
- 这种关节特异性应答模式在所有b/tsDMARDs中一致。
临床怎么用
- 对于腕关节、MCP2和MCP3关节受累的RA患者,使用b/tsDMARDs时应考虑延长治疗反应评估期。
- 当这些关节受累时,可考虑关节腔内激素桥接注射。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Whether treatment response differs across affected joints in rheumatoid arthritis (RA) remains unclear. We sought to determine whether responses to tumour necrosis factor inhibitors (TNFi) and other biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) vary across individual joints in a large cohort of patients with RA. METHODS: Patients with RA from the Swiss Clinical Quality Management in Rheumatic Diseases registry with ≥1 swollen joint at treatment initiation of a b/tsDMARD (abatacept, interleukin-6 receptor inhibitor (IL-6Ri), Janus kinase inhibitor (JAKi), rituximab and TNFi) were included. Time to resolution of swollen joints was evaluated over a 2-year follow-up using mixed effects models accounting for interval-censored data. The analyses compared the speed of improvement of individual joints within the 28-joint count to that of the wrist. The primary analysis focused on bio-naïve patients initiating TNFi treatment, while secondary analyses included all b/tsDMARD classes, irrespective of treatment line. RESULTS: A TNFi was initiated in 598 patients with ≥1 swollen joint, while 1942 patients with ≥1 swollen joint started a b/tsDMARD (abatacept: 242, IL-6Ri: 317, JAKi: 333, rituximab: 176, TNFi: 874). Compared with the wrist, all joints demonstrated higher rates of resolution, except for the second and third metacarpophalangeal (MCP2/3) joints and, in some analyses, the knee. This pattern of joint-specific response was consistent across all b/tsDMARDs. CONCLUSIONS: The wrist, MCP2 and MCP3 joints resolve more slowly than other joints following treatment with b/tsDMARDs, indicating that a longer evaluation period of treatment response and/or bridging intra-articular steroid injections may be required when these joints are affected.
引用
- Steimer A, Götschi A, Brändli J, et al. Site-specific articular responses to b/tsDMARDs in rheumatoid arthritis: a longitudinal observational study from the Swiss Clinical Quality Management Registry. RMD Open. 2026. PMID: 42336611. doi:10.1136/rmdopen-2026-007034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。